Clinical pharmacologic considerations for the phase II/III dose/regimen of the investigational Aurora A kinase (AAK) inhibitor MLN8237 (alisertib): Pharmacokinetics (PK), pharmacodynamics (PD), and exposure-safety relationships.
Karthik Venkatakrishnan
Employment or Leadership Position - Millennium
Xiaofei Zhou
Employment or Leadership Position - Millennium
Jeffrey Ecsedy
Employment or Leadership Position - Millennium
Hadi Danaee
Employment or Leadership Position - Millennium
Hugh Xiao
Employment or Leadership Position - Millennium
Hongliang Shi
Employment or Leadership Position - Millennium
Diane R. Mould
Consultant or Advisory Role - Projections Research
Howard Fingert
Employment or Leadership Position - Millennium
Ely Benaim
Employment or Leadership Position - Millennium
Stock Ownership - Millennium
Robert Kleinfield
Employment or Leadership Position - Millennium
Ashley Milton
Employment or Leadership Position - Millennium